BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 35925450)

  • 1. Association between intravenous immunoglobulin dose and outcomes in patients with acute Kawasaki disease.
    Michihata N; Suzuki T; Yoshikawa T; Saito K; Matsui H; Fushimi K; Yasunaga H
    Eur J Pediatr; 2022 Oct; 181(10):3607-3615. PubMed ID: 35925450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium-containing versus sodium-trace preparations of IVIG for children with Kawasaki disease in the acute phase.
    Suzuki T; Michihata N; Aso S; Yoshikawa T; Saito K; Matsui H; Fushimi K; Yasunaga H
    Eur J Pediatr; 2021 Nov; 180(11):3279-3286. PubMed ID: 33973071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between aspirin dose and outcomes in patients with acute Kawasaki disease: a nationwide retrospective cohort study in Japan.
    Suzuki T; Michihata N; Hashimoto Y; Yoshikawa T; Saito K; Matsui H; Fushimi K; Yasunaga H
    Eur J Pediatr; 2024 Jan; 183(1):415-424. PubMed ID: 37917176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose versus low-dose intravenous immunoglobulin for treatment of children with Kawasaki disease weighing 25 kg or more.
    Suzuki T; Michihata N; Yoshikawa T; Hata T; Matsui H; Fushimi K; Yasunaga H
    Eur J Pediatr; 2020 Dec; 179(12):1901-1907. PubMed ID: 32862279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
    Hsieh KS; Weng KP; Lin CC; Huang TC; Lee CL; Huang SM
    Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low- versus high-concentration intravenous immunoglobulin for children with Kawasaki disease in the acute phase.
    Suzuki T; Michihata N; Yoshikawa T; Saito K; Matsui H; Fushimi K; Yasunaga H
    Int J Rheum Dis; 2022 May; 25(5):576-583. PubMed ID: 35258165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Retrospective Cohort Study of Intravenous Immunoglobulin Therapy in the Acute Phase of Kawasaki Disease: The Earlier, the Better?
    Li W; He X; Zhang L; Wang Z; Wang Y; Lin H; Yuan J; Xie X; Qin Y; Huang P
    Cardiovasc Ther; 2021; 2021():6660407. PubMed ID: 34239607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk Factors for Coronary Artery Aneurysm in a Chinese Pediatric Population with Kawasaki Disease at Low Risk of Intravenous Immunoglobulin Resistance: A Retrospective Cohort Study.
    Liu J; Su D; Yuan P; Ye B; Qin S; Pang Y
    Cardiology; 2023; 148(5):457-468. PubMed ID: 37231847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
    Khowsathit P; Hong-Hgam C; Khositseth A; Wanitkun S
    J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1121-6. PubMed ID: 12549785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between post-IVIG IgG levels and clinical outcomes in Kawasaki disease patients: new insight into the mechanism of action of IVIG.
    Goto R; Inuzuka R; Shindo T; Namai Y; Oda Y; Harita Y; Oka A
    Clin Rheumatol; 2020 Dec; 39(12):3747-3755. PubMed ID: 32458247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of Coronary Artery Abnormalities with Fever Pattern in Patients with Kawasaki Disease.
    Tanaka A; Inoue M; Hoshina T; Koga H
    J Pediatr; 2021 Sep; 236():95-100. PubMed ID: 34019881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
    Miyata K; Kaneko T; Morikawa Y; Sakakibara H; Matsushima T; Misawa M; Takahashi T; Nakazawa M; Tamame T; Tsuchihashi T; Yamashita Y; Obonai T; Chiga M; Hori N; Komiyama O; Yamagishi H; Miura M;
    Lancet Child Adolesc Health; 2018 Dec; 2(12):855-862. PubMed ID: 30337183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Timing of intravenous immunoglobulin treatment and risk of coronary artery abnormalities in children with Kawasaki disease.
    Bal AK; Prasad D; Umali Pamintuan MA; Mammen-Prasad E; Petrova A
    Pediatr Neonatol; 2014 Oct; 55(5):387-92. PubMed ID: 24636168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials.
    Lei WT; Chang LS; Zeng BY; Tu YK; Uehara R; Matsuoka YJ; Su KP; Lee PC; Cavalcante JL; Stubbs B; Lin PY; Wu YC; Hsu CW; Chen TY; Chen YW; Yeh PY; Sun CK; Tseng PT; Kao YH
    EBioMedicine; 2022 Apr; 78():103946. PubMed ID: 35306339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infliximab for intensification of primary therapy for patients with Kawasaki disease and coronary artery aneurysms at diagnosis.
    Miyata K; Bainto EV; Sun X; Jain S; Dummer KB; Burns JC; Tremoulet AH
    Arch Dis Child; 2023 Oct; 108(10):833-838. PubMed ID: 37258054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of intravenous immunoglobulin resistance and coronary artery aneurysm in patients with Kawasaki disease.
    Chantasiriwan N; Silvilairat S; Makonkawkeyoon K; Pongprot Y; Sittiwangkul R
    Paediatr Int Child Health; 2018 Aug; 38(3):209-212. PubMed ID: 29768976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of different doses of aspirin on the prognosis of Kawasaki disease.
    Wang J; Chen H; Shi H; Zhang X; Shao Y; Hang B; Xu Z; Rong X; Chu M; Qiu H
    Pediatr Rheumatol Online J; 2020 Jun; 18(1):48. PubMed ID: 32527316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The time option of IVIG treatment is associated with therapeutic responsiveness and coronary artery abnormalities but not with clinical classification in the acute episode of Kawasaki disease.
    Samadli S; Liu FF; Mammadov G; Wang JJ; Liu HH; Wu YF; Luo HH; Wu Y; Chen WX; Zhang DD; Wei W; Hu P
    Pediatr Rheumatol Online J; 2019 Jul; 17(1):53. PubMed ID: 31366406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Kawasaki disease using locally product intravenous immunoglobulin.
    Sangtawesin C; Kirawitaya T; Layangkool T; Nawasiri W; Vimolsarawong N
    J Med Assoc Thai; 2003 Aug; 86 Suppl 3():S656-60. PubMed ID: 14700163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delayed Development of Coronary Artery Aneurysm in Patients with Kawasaki Disease Who Were Clinically Responsive to Immunoglobulin.
    Matsuoka R; Furuno K; Nanishi E; Onoyama S; Nagata H; Yamamura K; Sugitani Y; Kuraoka A; Mizuno Y; Sagawa K; Honjo S; Hara T; Ohga S
    J Pediatr; 2020 Dec; 227():224-230.e3. PubMed ID: 32810506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.